VICENTE
ESTRADA PÉREZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublications in collaboration with researchers from Hospital Universitario Príncipe de Asturias (26)
2023
-
Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry
Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
-
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
Predictors of poor prognosis in healthy, young, individuals with SARS-CoV-2 infections
Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 273-278
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Impact of smoking on COVID-19 outcomes: A HOPE Registry subanalysis
BMJ Nutrition, Prevention and Health, Vol. 4, Núm. 1, pp. 285-292
-
Underlying heart diseases and acute covid-19 outcomes
Cardiology Journal, Vol. 28, Núm. 2, pp. 202-214
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2018
-
Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study
Open Forum Infectious Diseases, Vol. 5, Núm. 1
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
-
Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47
2014
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2009
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201
2007
-
Cervical lipomatosis in HIV-infected patients: A case-control study
HIV Medicine, Vol. 8, Núm. 1, pp. 17-21
-
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study
AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241